COMPANY PROFILE

TargImmune Therapeutics

Explore full profile

Developing novel targeted immuno-oncology drugs

Basel, SwitzerlandFounded 2016Biotech & Life Sciences

Valuation $50–100M Last recorded · 2021

Revenue <$1M Latest reported FY

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About TargImmune Therapeutics

TargImmune Therapeutics AG is a Swiss-based biotechnology startup focused on revolutionizing cancer treatment. The company is dedicated to significantly improving the survival rates of cancer patients through its innovative portfolio of oncology compounds. TargImmune operates in the highly specialized and competitive field of cancer therapeutics, targeting a global market that includes hospitals, research institutions, and pharmaceutical companies.

Read full description

The core of TargImmune's business model is its groundbreaking modular, synthetic, targeted nucleic acid delivery platform. This platform is the first of its kind, known as Targeted Apoptosis and Immune Modulators (TAIMs). It uses synthetic nanoparticles to deliver nucleic acid therapeutics directly to cancer cells. Nucleic acids are molecules that carry genetic information, and by targeting these directly, TargImmune aims to induce apoptosis (cell death) in cancer cells and modulate the immune system to better fight cancer.

TargImmune generates revenue through the development and commercialization of its proprietary cancer treatment compounds. The company collaborates with pharmaceutical firms and research institutions, licensing its technology and forming strategic partnerships to bring its treatments to market. Additionally, TargImmune is open to discussions with potential investors to secure funding for further research and development.

The company's leadership team, including Chairman Dr. Kuno Sommer and Vice Chairman Dr. Peter Kash, brings a wealth of experience and scientific expertise, which is crucial for navigating the complexities of cancer treatment development. TargImmune is actively expanding its team to meet its ambitious goals and welcomes approaches from professionals interested in joining their mission.

In summary, TargImmune Therapeutics AG is a pioneering biotech company dedicated to transforming cancer treatment through its novel targeted nucleic acid delivery platform, aiming to improve patient survival rates and outcomes.

Source: Dealroom company data

At a glance

Status: Acquired
Founded: 2016
Headquarters: Basel, Switzerland
Employees: 5
Open positions: None listed
Dealroom signal: 59.5/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Oncology, Drug Development, Biotech and Pharma, Hard Tech, Horizon Europe, DT and LS, science-based, Swiss DT Biotech
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
ACQUISITION✓Exit	Mar 2025	$0	—	Ioncologi	↗
EARLY VC✓Equity / VC	Jul 2021	$16M	$65M	Undisclosed	—

Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Financials

Revenue over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth
2026
2025
2024
2023
2022
2021
2020		—

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

TargImmune Therapeutics website traffic

Latest recorded traffic for TargImmune Therapeutics is 90 monthly website visits, down 83.3% over the last three months. TargImmune Therapeutics's team declined 28.6% over the past year.

Latest monthly visits90 3-month web change-83.3% 1-year team growth-28.6%

Monthly website visitsOct 2018–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
LHLegacy HealthcareBiopharma developing innovative botanical drugs in supportive oncology care and dermatology	Epalinges, Switzerland	Operational	9	$4.3M	$7.5M
NTNEOGAP TherapeuticsImagine if cancer patients who lack efficient treatment options could be cured	Stockholms kommun, Sweden	Operational
ATAtG TherapeuticsAt AtG, we develop novel classes of medicines and biomarkers to prevent cancer therapeutic resistance	L'Hospitalet de Llobregat, Spain	Operational
CTCeleris TherapeuticsPredicting biomolecular interactions and designing drugs for incurable diseases	Graz, Austria	Operational
PHPhilogenDevelop innovative biopharmaceuticals for the treatment of angiogenesis-related disorders	Sovicille, Italy	Operational
SLSartar Therapeutics Ltd.Developing a new precision medicine product to treat sarcomas	Helsinki, Finland	Operational
ATAchilles TherapeuticsAchilles Tx's mission is to develop next-generation, patient-specific therapies that harness the immune system to destroy cancer cells	Stevenage, United Kingdom	Closed
SOSentinel OncologyTargeted oncology candidate drugs for brain tumours	Cambridge, United Kingdom	Operational